Margin uplift set to continue in Q4. Limited revisions on adj. EBITDA. BUY case confirmed, TP up to SEK 62 (59).

19 Oct 2023
Impressive cash flow generation in Q3

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Impressive cash flow generation in Q3
- Published:
19 Oct 2023 -
Author:
ABGSC Healthcare Research | Sten Gustafsson -
Pages:
17 -
Margin uplift set to continue in Q4. Limited revisions on adj. EBITDA. BUY case confirmed, TP up to SEK 62 (59).